Randomised Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Primary Results of the BERSON Clinical Trial.

Alberto J Lorenzatti,Freddy G Eliaschewitz,Yundai Chen,Juming Lu,Alexis Baass,Maria Laura Monsalvo,Nan Wang,Andrew W Hamer,Junbo Ge

Journal of Clinical Lipidology（2019）

引用 27|浏览51

暂无评分

摘要

In patients with T2DM and hyperlipidaemia or mixed dyslipidaemia on statin, evolocumab significantly reduced LDL-C and other atherogenic lipids, was well tolerated, and had no notable impact on glycaemic measures. This article is protected by copyright. All rights reserved.

查看译文

关键词

dyslipidaemia,evolocumab,hyperlipidaemia,phase 3,type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要